FMC Corporation has submitted the regulatory dossier for rimisoxafen to the United States Environmental Protection Agency (EPA), marking the first global regulatory submission for this herbicide active ingredient. The submission covers use on corn, soybean, sunflower and select pulse crops, addressing intensifying weed resistance pressure in key row crop markets.

Filing the dossier represents a significant milestone for FMC, according to Seva Rostovtsev, executive vice president and chief technology officer at FMC. The company stated that years of innovation and scientific discovery led to this breakthrough dual mode of action technology, designed to help growers facing complex weed resistance challenges.

Discovered at FMC's Stine Research Center, rimisoxafen is built on over a decade of biology research and more than 1,000 field and greenhouse studies. It is the first herbicide active ingredient classified as a dual mode of action by the Global Herbicide Resistance Action Committee (HRAC). Designated under Groups 12 and 32, the ingredient inhibits two distinct biochemical pathways in weeds, which helps delay resistance development compared to single mode of action herbicides.

Herbicide-resistant weeds continue to challenge growers and drive demand for new modes of action. According to a 2025 Weed Science Society of America National Weed Survey, Palmer amaranth and waterhemp rank as the most troublesome broadleaf weeds in U.S. soybean production. In extensive field testing, rimisoxafen has demonstrated consistent activity against both. The U.S. represents a critical market for next-generation weed control solutions with more than 70 million hectares of corn and soybeans grown annually and growers spending more than $6 billion annually on weed control.

Rimisoxafen is the third novel herbicide active ingredient FMC has advanced to regulatory submission in recent years, following Isoflex active and Dodhylex active. FMC intends to pursue regulatory submissions for rimisoxafen in additional key geographies and crop segments as part of its global development program. Timing and outcomes are subject to regulatory review and approval in each jurisdiction. Rimisoxafen is not currently registered for sale or use in the United States or any other country.

FMC Corporation has entered into a definitive agreement for Tessenderlo Group to make a strategic minority equity investment of approximately $400 million at a price of $13.30 per share. This transaction will allow Tessenderlo Group to own approximately 20.0% of the outstanding shares of FMC common stock. FMC intends to use the funds to pay down debt, enabling the company to reach its approximately $1 billion debt paydown target and improve its financial flexibility.

The agreement concludes the FMC Board of Directors' exploration of strategic options announced in February 2026. Pierre Brondeau, chairman, chief executive officer and president of FMC, stated that the Board is confident this agreement is the best path forward for the company and its shareholders. The company will continue to execute its operational and strategic plan as an independent entity, focusing on advancing its R&D pipeline and accelerating the commercialization of innovations.

Luc Tack, chief executive officer of Tessenderlo Group, said the investment aligns with the group's strategy to expand its agro platform through cornerstone minority positions in high-quality companies. He cited FMC's long-term potential driven by a new generation of proprietary molecules that are renewing its portfolio.

Strategic and Financial Actions

In addition to the equity investment, FMC has undertaken several measures over recent months to unlock capital and sharpen its strategic focus. These actions include:

• Amending its Revolving Credit Facility to achieve significant covenant relief.
• Raising $1.2 billion in a secured high-yield bond offering.
• Signing an agreement to sell the Company's India commercial business for $252 million.
• Entering into a strategic supply and license agreement with Corteva, Inc., which includes an initial prepayment of $200 million.
• Signing a framework agreement for a $114 million sale & leaseback of its Newark, Delaware property.

Transaction Details

The closing of the transaction is subject to customary conditions, including the receipt of regulatory approvals. BofA Securities and Goldman Sachs & Co. LLC are serving as financial advisors to FMC Corporation, with Davis Polk & Wardwell LLP as legal counsel. Stibbe BV/SRL and Sullivan & Cromwell LLP are serving as legal advisors to Tessenderlo Group.